Sinotherapeutics Inc. (SHA:688247)

China flag China · Delayed Price · Currency is CNY
9.30
+0.14 (1.53%)
At close: Apr 30, 2026
-6.53%
Market Cap 4.11B
Revenue (ttm) 446.57M
Net Income (ttm) 47.48M
Shares Out 449.00M
EPS (ttm) 0.11
PE Ratio 83.27
Forward PE n/a
Dividend 0.05 (0.55%)
Ex-Dividend Date n/a
Volume 2,567,592
Average Volume 2,305,108
Open 9.23
Previous Close 9.16
Day's Range 9.15 - 9.38
52-Week Range 8.85 - 13.28
Beta 0.20
RSI 46.34
Earnings Date Apr 30, 2026

About Sinotherapeutics

Sinotherapeutics Inc., a specialty pharmaceutical company, research, develops, manufactures, and commercializes generic and formulation products in China. The company’s products are indicated for infection, oncology and rheumatology, gastroenterology and metabolism, neurology, cardiology, and nephrology. It offers posaconazole delayed-release tablets; olaparib, exemestane, and tofacitinib extended-release tablets; and mesalamine delayed-release, dapagliflozin and metformin hydrochloride sustained-release, sitagliptin and metformin hydrochloride... [Read more]

Sector Healthcare
Founded 2012
Employees 312
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 688247
Full Company Profile

Financial Performance

In 2025, Sinotherapeutics's revenue was 446.57 million, a decrease of -12.71% compared to the previous year's 511.62 million. Earnings were 47.48 million, a decrease of -62.82%.

Financial Statements

News

There is no news available yet.